Longitudinal molecular analysis of P. vivax and P. falciparum infections before and after implementation of Artemisinin-Based Combination Therapy in Papua, Indonesia
Background. The province of Papua has the highest burden of malaria in Indonesia, with both drug resistant P. vivax and P. falciparum prevalent. As a consequence of the declining efficacy of CQ in the region, Papua-Indonesia became one of the first regions to implement a unified artemisinin-based combination therapy (ACT) policy of dihydroartemisinin-piperaquine for all species of malaria in March 2006. The current study characterizes the impact of ACT implementation on the genetic diversity and population structure of co-endemic P. vivax and P. falciparum populations. Materials and Methods. The study was conducted in Mimika District, in southern Papua Province. Microsatellite typing was undertaken on randomly selected parasite isolates (231 P. falciparum and 225 P. vivax) collected between 2004 and 2006 (pre-ACT) and between 2011 and 2016 (post-ACT) from symptomatic patients with uncomplicated malaria. Results. There was a significant decrease in the proportion of polyclonal P. vivax infections after ACT implementation (57% (43/75) to 33% (49/150); p=0.001), although no signs of decreasing genetic diversity or inbreeding events were found. The P. falciparum population also demonstrated a decline in the proportion of polyclonal infections post-ACT (18% (16/91) to 9% (13/139); p=0.104), as well as increased inbreeding and prevalence of identical infections (24% (21/89) versus 46% (60/130); p=0.001). Conclusions. The implementation of ACT reduced transmission of both P. falciparum and P. vivax. The impact on P. falciparum was greater as evidenced by the degree of population bottlenecking relative to P. vivax. Anti-relapse therapy is likely to be a key component to achieve the same impact in P. vivax.